Rubicon Founders LLC Buys Shares of 5,971,079 Privia Health Group, Inc. $PRVA

Rubicon Founders LLC acquired a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 5,971,079 shares of the company's stock, valued at approximately $153,635,863. Privia Health Group makes up 0.1% of Rubicon Founders LLC's holdings, making the stock its largest position. Rubicon Founders LLC owned 4.67% of Privia Health Group at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of PRVA. Royal Bank of Canada lifted its holdings in Privia Health Group by 63.5% in the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company's stock valued at $5,514,000 after purchasing an additional 95,371 shares in the last quarter. AQR Capital Management LLC raised its holdings in Privia Health Group by 24.7% in the 1st quarter. AQR Capital Management LLC now owns 40,781 shares of the company's stock worth $916,000 after acquiring an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Privia Health Group by 3.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company's stock worth $2,666,000 after purchasing an additional 3,714 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Privia Health Group by 55.1% in the 1st quarter. Intech Investment Management LLC now owns 56,553 shares of the company's stock valued at $1,270,000 after acquiring an additional 20,082 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Privia Health Group in the first quarter valued at approximately $154,000. Hedge funds and other institutional investors own 94.48% of the company's stock.

Privia Health Group Trading Down 0.0%

Shares of Privia Health Group stock traded down $0.01 on Friday, reaching $20.85. 425,259 shares of the company were exchanged, compared to its average volume of 989,683. Privia Health Group, Inc. has a one year low of $19.53 and a one year high of $28.82. The company has a 50-day moving average of $24.39 and a 200 day moving average of $23.20. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of 99.29, a PEG ratio of 1.66 and a beta of 0.85.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.07 by $0.12. Privia Health Group had a net margin of 1.19% and a return on equity of 3.52%. The company had revenue of $632.63 million for the quarter, compared to the consensus estimate of $597.33 million. During the same quarter in the previous year, the company earned $0.24 EPS. Privia Health Group's quarterly revenue was up 21.4% compared to the same quarter last year. Analysts predict that Privia Health Group, Inc. will post 0.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on PRVA shares. Weiss Ratings raised Privia Health Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, July 2nd. Canaccord Genuity Group set a $32.00 price target on shares of Privia Health Group in a research note on Friday, August 7th. Zacks Research upgraded shares of Privia Health Group from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 5th. Citigroup reaffirmed a "buy" rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Finally, Barclays reduced their price target on Privia Health Group from $25.00 to $24.00 and set an "equal weight" rating for the company in a report on Tuesday, May 26th. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.00.

Insider Activity at Privia Health Group

In other news, CFO David Mountcastle sold 24,734 shares of the firm's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total transaction of $680,185.00. Following the sale, the chief financial officer owned 186,728 shares of the company's stock, valued at $5,135,020. This trade represents a 11.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $25.33, for a total value of $2,231,826.30. Following the completion of the sale, the director owned 76,651 shares in the company, valued at approximately $1,941,569.83. The trade was a 53.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 327,886 shares of company stock valued at $8,628,256. 5.70% of the stock is currently owned by company insiders.

Privia Health Group Company Profile

Privia Health Group NASDAQ: PRVA is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.